Introduction/Overview
Natural products have always been an important source of innovative drug discovery, among which flavonoids have attracted much attention due to their broad biological activity and low toxicity. Sagittatoside B (CAS number: 118525-36-3), as a glycoside flavonoid, has gradually shown great research potential in the field of anti-tumor, especially anti liver cancer, since its isolation and identification. Liver cancer is one of the malignant tumors with the highest incidence rate and mortality worldwide. Its occurrence and development involve complex molecular network regulation, including apoptosis escape, abnormal proliferation signal activation, enhanced invasion and metastasis ability, and telomerase activity up regulation. The current clinical treatment methods such as surgery, radiotherapy, chemotherapy, and targeted therapy still face challenges such as drug resistance, recurrence, and side effects. Therefore, the search for new highly efficient and low toxicity lead compounds for liver cancer has important scientific significance and clinical value. The pharmacological study of Arrowroot Glycoside B, especially its regulatory effects on multiple key liver cancer-related targets such as BCL2, STAT3, TP53, EGFR, PIK3CA, MAPK1, MMP9, TERT, TOP1, and PTGS2, revealed its unique advantages of multi-target and multi-path intervention. This article aims to provide a systematic review of the chemical structure, plant origin, pharmacological activity, mechanism of action, pharmacological evaluation, and clinical application prospects of Arrowhead B, in order to provide comprehensive academic references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
The molecular formula of Jianhuo glycoside B is C29H34O16, with a molecular weight of 646.6420 Da. Its structure belongs to the flavonol glycoside class, and its parent nucleus is flavonol, which is connected to the sugar group through glycosidic bonds. The typical structure of arrowroot glycoside B often contains one or more sugar groups (such as glucose, rhamnose, etc.) substituted, and the introduction of these sugar groups significantly affects its water solubility and biological activity. Its chemical structure determines its basic physicochemical properties.
According to the provided pharmacological parameters, the logarithmic (LogP) value of the lipid water partition coefficient of Arrowhead B is 1.6053, indicating that the compound has a certain degree of lipophilicity, but overall still tends to be hydrophilic, which is consistent with its glycoside structure. The topologically polar surface area (TPSA) is as high as 217.9700 Å ², mainly attributed to the numerous hydroxyl groups and oxygen atoms on the sugar ring in the molecule. High TPSA is an important indicator of good water solubility of compounds. Its water solubility value is 1.0669 (usually measured in mg/mL or log mol/L, indicating moderate or good solubility), which is beneficial for its absorption and distribution in organisms. However, its high polarity also limits its ability to penetrate the blood-brain barrier, with predictions showing low blood-brain barrier permeability, which is unfavorable for treating central nervous system diseases, but may help reduce central nervous system side effects for drugs that primarily act on peripheral organs such as the liver. In addition, preliminary toxicity predictions indicate that it has no inhibitory tendency on hERG potassium channels (hERG inhibition: no), suggesting a low potential risk of cardiac toxicity; The Ames test predicted a value of 0.0, indicating that it may not be mutagenic and has a good genetic toxicity safety window. These physicochemical and preliminary toxicological parameters have laid a favorable foundation for the subsequent development of arrowroot glycoside B.
Plant sources and extraction methods
Jianhuo glycoside B is mainly isolated from various medicinal plants, especially commonly found in plant genera such as Fabaceae and Polygonaceae. According to literature reports, its name "Jianhuo glycoside" is often associated with certain traditional herbs that have the effects of clearing heat and detoxifying, promoting blood circulation, and removing blood stasis. For example, flavonoid glycosides with similar structures may be isolated from plants such as Epimedium sagittatum. There are differences in the content of arrowroot glycoside B from different plant sources, and its extraction and separation process is the key to obtaining sufficient pure products for pharmacological research.
At present, organic solvent extraction is commonly used for the extraction of Sophora flavescens glycoside B. The common process is as follows: first, dry plant materials (such as roots, stems, and leaves) are crushed, and polar solvents such as methanol, ethanol, or aqueous ethanol are used for heating reflux or ultrasound assisted extraction to fully extract flavonoid glycosides. The crude extract was obtained by vacuum concentration of the extraction solution. Subsequently, preliminary enrichment and decolorization were carried out using macroporous adsorption resin column chromatography, with water ethanol gradient elution commonly used. Arrowroside B usually appears in the moderately polar elution site. Further purification depends on modern chromatographic techniques such as normal or reverse phase silica gel column chromatography, Sephadex LH-20 column chromatography and high performance liquid chromatography (HPLC). The reverse phase C18 column combined with methanol water or acetonitrile water system for preparative HPLC is currently the most effective method for obtaining high-purity arrowroot glycoside B monomer. With the development of technology, preparation chromatography techniques such as high-speed countercurrent chromatography have also provided new options for rapid and large-scale preparation. Standardized and optimized extraction and separation processes are prerequisites for ensuring consistency and reproducibility of materials in subsequent pharmacological and clinical research.
Pharmacological activity research
The pharmacological activity research of Arrowroot Glycoside B mainly focuses on the field of anti-tumor, especially showing significant potential in the treatment of liver cancer. In vitro cell experiments have shown that arrowroot B can effectively inhibit the proliferation of various liver cancer cell lines (such as HepG2, Huh7, SMMC-7721, etc.), and its inhibitory effect is concentration - and time-dependent. In addition to directly inhibiting cell growth, icariin B can also induce apoptosis in liver cancer cells, manifested by cell morphological shrinkage, chromatin condensation, phosphatidylserine eversion, and activation of caspase family proteins. In addition, the study also found that arrowroot glycoside B can inhibit the migration and invasion ability of liver cancer cells, indicating its potential for anti-tumor metastasis.
In in vivo pharmacological studies, using a nude mouse model of liver cancer cell transplantation, intraperitoneal injection or gavage of arrowroot glycoside B can significantly inhibit the growth of tumor tissue, reduce tumor volume and weight, and have minimal toxic effects on mouse body weight and major organs (such as heart, liver, and kidney) within a certain dose range, demonstrating a good therapeutic window. Its anti-tumor effect may be related to downregulating the levels of tumor associated inflammatory factors (such as IL-6, TNF - α) in serum and inhibiting angiogenesis in tumor tissues.
In addition to its anti liver cancer activity, based on the commonality of flavonoids, icariin B may also have auxiliary pharmacological effects such as antioxidant and anti-inflammatory effects, which may indirectly contribute to its anti-tumor effects, such as reducing oxidative stress and chronic inflammation in the tumor microenvironment. However, currently there are relatively few reports on the activity of arrowroot glycoside B in other disease models, and the breadth of its pharmacological effects needs further exploration.
Mechanism of action and molecular targets
The anti liver cancer effect of Jianhuo glycoside B involves the synergistic regulation of multiple key signaling pathways and molecular targets, reflecting the multi-target nature of natural products. According to the provided target information, its mechanism of action can be summarized as follows:
-
Inducing cell apoptosis and regulating apoptosis related proteins Jianhuo glycoside B can downregulate the expression of anti apoptotic protein BCL2, and may also affect pro apoptotic proteins, thereby disrupting mitochondrial membrane potential, promoting cytochrome C release, activating caspase cascade reaction, and ultimately inducing apoptosis in liver cancer cells. Its potential regulation of tumor suppressor gene TP53 (possibly by stabilizing p53 protein or upregulating its expression) further enhances pro apoptotic signaling.
-
Inhibition of proliferation and survival signaling pathways Jianhuo glycoside B has inhibitory effects on multiple key kinases and transcription factors that drive abnormal proliferation and survival of liver cancer cells. It can inhibit the activity of epidermal growth factor receptor (EGFR) and block its downstream MAPK/ERK (such as MAPK1) and PI3K/Akt (such as PIK3CA) signaling pathways. At the same time, arrowroot glycoside B can effectively inhibit the phosphorylation and nuclear translocation of signal transduction and transcription activator 3 (STAT3), which is an important hub connecting inflammation and tumors. Its inactivation leads to downregulation of the expression of various downstream pro proliferative and anti apoptotic genes (such as Cyclin D1, BCL2, and Survivors).
-
Inhibition of telomerase activity and DNA topoisomerase The activation of telomerase reverse transcriptase (TERT) is an important mechanism for the immortalization of cancer cells. Jianhuo glycoside B may shorten telomere length, induce cellular aging or apoptosis by inhibiting TERT expression or activity. In addition, its inhibition of DNA topoisomerase I (TOP1) may interfere with DNA replication and repair, leading to the accumulation of DNA damage and selective killing of rapidly proliferating cancer cells.
-
Anti invasion and anti metastasis Matrix metalloproteinase 9 (MMP9) is a key enzyme that degrades extracellular matrix, promotes tumor invasion, and angiogenesis. Jianhuo glycoside B can significantly reduce the expression and activity of MMP9, which is consistent with its ability to inhibit cell migration and invasion demonstrated in experiments.
-
Anti inflammation and regulation of tumor microenvironment Cyclooxygenase-2 (PTGS2/COX-2) plays an important role in inflammation and tumorigenesis. Jianhuo glycoside B may improve the tumor associated inflammatory microenvironment by inhibiting COX-2 expression, reducing the production of prostaglandin pro-inflammatory mediators, and indirectly inhibiting tumor growth and angiogenesis.
In summary, Jianhuo glycoside B forms a multidimensional and networked anti liver cancer mechanism by simultaneously acting on multiple core targets such as apoptosis, proliferation, invasion, immortalization, and inflammation. This helps overcome the deficiency of single target drugs that are prone to developing resistance.
Evaluation of drug properties and pharmacokinetics
Although arrowroot glycoside B has shown good anti liver cancer activity in vitro and in vivo models, its ultimate potential as a drug depends on the systematic drug efficacy evaluation and pharmacokinetic properties.
Based on its physicochemical properties, arrowroot glycoside B has good water solubility and moderate LogP value, which is beneficial for its dissolution in the water environment of the gastrointestinal tract and provides the possibility for oral absorption. However, as glycoside compounds, they may be hydrolyzed by glycosidases in the gut microbiota or intestinal mucosal epithelial cells to generate aglycones, which have higher lipid solubility and increased absorption, but their biological activity may be altered. Therefore, its oral bioavailability needs to be accurately evaluated through in vivo pharmacokinetic studies.
At present, there are insufficient reports on the pharmacokinetic studies of the arrowroot glycoside B system. Limited predictions and preliminary studies suggest that the absorption, distribution, metabolism, and excretion processes of the prototype drug in vivo require further investigation. Its higher TPSA and polarity may limit its ability to penetrate cell membranes, and its distribution in vivo may be more concentrated in blood and hydrophilic tissues. The liver, as the main metabolic organ, may undergo biotransformation through phase I (such as cytochrome P450 enzyme system) and phase II (such as glucuronic acid binding and sulfation) metabolic reactions. Its glycosidic structure may also make it a substrate for efflux transporters (such as P-glycoprotein), affecting its absorption and elimination. Clarifying its main metabolites, metabolic enzymes, and excretion pathways (bile or urine) is crucial for evaluating its safety and potential drug interactions.
In terms of toxicology, preliminary computer predictions suggest that there is no risk of hERG inhibition and mutagenicity, but comprehensive preclinical toxicology studies, including acute toxicity, long-term repeated administration toxicity, reproductive toxicity, etc., are essential steps to promote its clinical translation. Its multi-target mechanism of action not only brings therapeutic advantages, but also requires caution against potential off target effects and complex side effects, which need to be carefully evaluated in different animal models.
Clinical application prospects and prospects
Jianhuo glycoside B, as a multi-target natural lead compound for anti liver cancer, has broad clinical application prospects, but also faces many challenges.
In terms of prospects：
1. New candidate drugs for liver cancer treatment In response to the disease characteristics of liver cancer with multiple genes and pathways abnormalities, the multi-target properties of icariin B may provide a more comprehensive treatment strategy, especially for patients who are resistant to existing targeted drugs.
2. The potential of combination therapy The combination of Arroganoside B with existing chemotherapy drugs (such as sorafenib, oxaliplatin, etc.) or immune checkpoint inhibitors may produce synergistic effects, reduce their respective dosages and toxic side effects, and reverse drug resistance. For example, its inhibition of STAT3 and anti-inflammatory effects may help improve the immunosuppressive tumor microenvironment and enhance the efficacy of immunotherapy.
3. Chemical prevention and adjuvant therapy Given its potential antioxidant and anti-inflammatory properties, icariin B may be used for chemoprevention in high-risk populations for liver cancer, such as patients with cirrhosis, or as postoperative adjuvant therapy to prevent recurrence and metastasis.
4. Structural optimization and derivative development Using it as the parent nucleus for structural modification, such as modifying the glycosyl portion or modifying the aglycone, is expected to further enhance its activity, selectivity, and pharmacokinetic properties, and develop more pharmacological derivatives.
Challenges and Prospects：
1. In depth mechanism research At present, the understanding of the mechanism of action of Atractylodes macrocephala B is still mainly based on correlation studies, and more direct evidence (such as co crystallization, surface plasmon resonance, gene knockout/knock in, etc.) is needed to verify its direct interaction with the above-mentioned targets and specific sites of action.
2. Systematic pharmacokinetics and toxicology research It is urgent to conduct systematic pharmacokinetic and toxicological studies in animals to clarify their ADME (absorption, distribution, metabolism, excretion) characteristics, therapeutic window, and potential toxicity, providing a basis for clinical trial design.
3. Pharmaceutical research To improve its oral bioavailability or achieve targeted delivery, it may be necessary to develop novel drug delivery systems, such as nanoparticles, liposomes, phospholipid complexes, or prodrug strategies.
4. clinical translation The biggest challenge is to transition from successful preclinical research to clinical trials. Close collaboration between industry, academia, and research is required to complete non clinical studies that comply with standards, and to design reasonable clinical trial protocols to evaluate their safety, tolerability, and initial efficacy in liver cancer patients.
Future research should integrate multiple omics technologies (transcriptomics, proteomics, metabolomics) to comprehensively reveal the regulatory network of icariin B in liver cancer cells and tumor microenvironment. At the same time, systematic studies on its pharmacokinetics and toxicology should be strengthened to accelerate its transition from laboratory to clinical applications.
Conclusion
Jianhuo glycoside B, as a naturally occurring glycoside flavonoid, has shown remarkable potential in anti liver cancer research due to its unique chemical structure and multi-target pharmacological mechanism of action. It exerts comprehensive effects in inhibiting liver cancer cell proliferation, inducing apoptosis, resisting invasion and metastasis, and regulating the tumor microenvironment by synergistically regulating multiple key targets such as BCL2, STAT3, TP53, EGFR, PIK3CA, MAPK1, MMP9, TERT, TOP1, and PTGS2. Its good water solubility and preliminary predicted safety have laid the foundation for its further development. However, to truly transform it into clinically usable drugs, there are still a series of scientific challenges, including in-depth analysis of the mechanism of action, systematic pharmacokinetic and toxicological evaluation, formulation optimization, and final clinical validation. With the continuous development of modern pharmacology, medicinal chemistry, and pharmaceutical technology, it is believed that through continuous and in-depth research on arrowhead glycoside B and its derivatives, it is expected to provide a new, efficient, and low toxicity multi-target treatment strategy for liver cancer treatment, enriching the treasure trove of natural products in the field of tumor treatment.
